Therapeutic targets associated to E-cadherin dysfunction in gastric cancer

Bibliography

• Christofori G. Changing neighbours, changing behaviour: cell adhesion molecule-mediated signalling during tumour progression. Embo J 2003;22:2318-23
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74
   PubMed Web of Science ®Google Scholar
• Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009;139:871-90
   PubMed Web of Science ®Google Scholar
• Christofori G. Snail1 links transcriptional control with epigenetic regulation. Embo J 2010;29:1787-9
   PubMed Web of Science ®Google Scholar
• David JM, Rajasekaran AK. Dishonorable discharge: the oncogenic roles of cleaved E-cadherin fragments. Cancer Res 2012;72(12):2917-23
   PubMed Web of Science ®Google Scholar
• Berx G, van Roy F. Involvement of members of the cadherin superfamily in cancer. Cold Spring Harb Perspect Biol 2009;1:a003129
   PubMed Web of Science ®Google Scholar
• Cavallaro U, Christofori G. Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat Rev Cancer 2004;4:118-32
   PubMed Web of Science ®Google Scholar
• Paredes J, Figueiredo J, Albergaria A, et al. Epithelial E- and P-cadherins: role and clinical significance in cancer. Biochim Biophys Acta 2012;1826:297-311
   PubMed Web of Science ®Google Scholar
• Canel M, Serrels A, Frame MC, Brunton VG. E-cadherin-integrin crosstalk in cancer invasion and metastasis. J Cell Sci 2013;126:393-401
   PubMed Web of Science ®Google Scholar
• Carneiro P, Fernandes MS, Figueiredo J, et al. E-cadherin dysfunction in gastric cancer–cellular consequences, clinical applications and open questions. FEBS Lett 2012;586:2981-9
   PubMed Web of Science ®Google Scholar
• van Roy F, Berx G. The cell-cell adhesion molecule E-cadherin. Cell Mol Life Sci 2008;65:3756-88
   PubMed Web of Science ®Google Scholar
• Birchmeier W, Behrens J. Cadherin expression in carcinomas: role in the formation of cell junctions and the prevention of invasiveness. Biochim Biophys Acta 1994;1198:11-26
   PubMed Web of Science ®Google Scholar
• Bracke ME, Van Roy FM, Mareel MM. The E-cadherin/catenin complex in invasion and metastasis. Curr Top Microbiol Immunol 1996;213(Pt 1):123-61
   PubMedGoogle Scholar
• Efstathiou JA, Liu D, Wheeler JM, et al. Mutated epithelial cadherin is associated with increased tumorigenicity and loss of adhesion and of responsiveness to the motogenic trefoil factor 2 in colon carcinoma cells. Proc Natl Acad Sci USA 1999;96:2316-21
   PubMed Web of Science ®Google Scholar
• Umbas R, Isaacs WB, Bringuier PP, et al. Relation between aberrant alpha-catenin expression and loss of E-cadherin function in prostate cancer. Int J Cancer 1997;74:374-7
   PubMed Web of Science ®Google Scholar
• Risinger JI, Berchuck A, Kohler MF, Boyd J. Mutations of the E-cadherin gene in human gynecologic cancers. Nat Genet 1994;7:98-102
   PubMed Web of Science ®Google Scholar
• Berx G, Becker KF, Hofler H, van Roy F. Mutations of the human E-cadherin (CDH1) gene. Hum Mutat 1998;12:226-37
   PubMed Web of Science ®Google Scholar
• Berx G, Cleton-Jansen AM, Nollet F, et al. E-cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers. Embo J 1995;14:6107-15
   PubMed Web of Science ®Google Scholar
• Machado JC, Soares P, Carneiro F, et al. E-cadherin gene mutations provide a genetic basis for the phenotypic divergence of mixed gastric carcinomas. Lab Invest 1999;79:459-65
   PubMed Web of Science ®Google Scholar
• Friedl P, Hegerfeldt Y, Tusch M. Collective cell migration in morphogenesis and cancer. Int J Dev Biol 2004;48:441-9
   PubMed Web of Science ®Google Scholar
• Rodriguez FJ, Lewis-Tuffin LJ, Anastasiadis PZ. E-cadherin's dark side: possible role in tumor progression. Biochim Biophys Acta 2012;1826:23-31
   PubMed Web of Science ®Google Scholar
• Guilford P, Hopkins J, Harraway J, et al. E-cadherin germline mutations in familial gastric cancer. Nature 1998;392:402-5
   PubMed Web of Science ®Google Scholar
• Barber M, Murrell A, Ito Y, et al. Mechanisms and sequelae of E-cadherin silencing in hereditary diffuse gastric cancer. J Pathol 2008;216:295-306
   PubMed Web of Science ®Google Scholar
• Perl AK, Wilgenbus P, Dahl U, et al. A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature 1998;392:190-3
   PubMed Web of Science ®Google Scholar
• Derksen PW, Liu X, Saridin F, et al. Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis. Cancer Cell 2006;10:437-49
   PubMed Web of Science ®Google Scholar
• Humar B, Blair V, Charlton A, et al. E-cadherin deficiency initiates gastric signet-ring cell carcinoma in mice and man. Cancer Res 2009;69:2050-6
   PubMed Web of Science ®Google Scholar
• Mimata A, Fukamachi H, Eishi Y, Yuasa Y. Loss of E-cadherin in mouse gastric epithelial cells induces signet ring-like cells, a possible precursor lesion of diffuse gastric cancer. Cancer Sci 2011;102:942-50
   PubMed Web of Science ®Google Scholar
• Shimada S, Mimata A, Sekine M, et al. Synergistic tumour suppressor activity of E-cadherin and p53 in a conditional mouse model for metastatic diffuse-type gastric cancer. Gut 2012;61:344-53
   PubMed Web of Science ®Google Scholar
• Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009;119:1420-8
   PubMed Web of Science ®Google Scholar
• Vleminckx K, Vakaet L Jr, Mareel M, et al. Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell 1991;66:107-19
   PubMed Web of Science ®Google Scholar
• Frixen UH, Behrens J, Sachs M, et al. E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. J Cell Biol 1991;113:173-85
   PubMed Web of Science ®Google Scholar
• Kuwabara Y, Yamada T, Yamazaki K, et al. Establishment of an ovarian metastasis model and possible involvement of E-cadherin down-regulation in the metastasis. Cancer Sci 2008;99:1933-9
   PubMed Web of Science ®Google Scholar
• Caldeira J, Pereira PS, Suriano G, Casares F. Using fruitflies to help understand the molecular mechanisms of human hereditary diffuse gastric cancer. Int J Dev Biol 2009;53:1557-61
   PubMed Web of Science ®Google Scholar
• Pagliarini RA, Xu T. A genetic screen in Drosophila for metastatic behavior. Science 2003;302:1227-31
   PubMed Web of Science ®Google Scholar
• Corso G, Carvalho J, Marrelli D, et al. Somatic mutations and deletions of the E-cadherin gene predict poor survival of patients with gastric cancer. J Clin Oncol 2013;31:868-75
   PubMed Web of Science ®Google Scholar
• Birchmeier W, Behrens J. Cadherin expression in carcinomas: role in the formation of cell junctions and the prevention of invasiveness. Biochim Biophys Acta 1994;1198:11-26
   PubMed Web of Science ®Google Scholar
• Christofori G, Semb H. The role of the cell-adhesion molecule E-cadherin as a tumour-suppressor gene. Trends Biochem Sci 1999;24:73-6
   PubMed Web of Science ®Google Scholar
• Oliveira C, Senz J, Kaurah P, et al. Germline CDH1 deletions in hereditary diffuse gastric cancer families. Hum Mol Genet 2009;18:1545-55
   PubMed Web of Science ®Google Scholar
• Oliveira C, de Bruin J, Nabais S, et al. Intragenic deletion of CDH1 as the inactivating mechanism of the wild-type allele in an HDGC tumour. Oncogene 2004;23:2236-40
   PubMed Web of Science ®Google Scholar
• Oliveira C, Sousa S, Pinheiro H, et al. Quantification of epigenetic and genetic 2nd hits in CDH1 during hereditary diffuse gastric cancer syndrome progression. Gastroenterology 2009;136:2137-48
   PubMed Web of Science ®Google Scholar
• Grady WM, Willis J, Guilford PJ, et al. Methylation of the CDH1 promoter as the second genetic hit in hereditary diffuse gastric cancer. Nat Genet 2000;26:16-17
   PubMed Web of Science ®Google Scholar
• Becker KF, Atkinson MJ, Reich U, et al. E-cadherin gene mutations provide clues to diffuse type gastric carcinomas. Cancer Res 1994;54:3845-52
   PubMed Web of Science ®Google Scholar
• Carvalho J, van Grieken NC, Pereira PM, et al. Lack of microRNA-101 causes E-cadherin functional deregulation through EZH2 up-regulation in intestinal gastric cancer. J Pathol 2012;228(1):31-44
   PubMed Web of Science ®Google Scholar
• Machado JC, Oliveira C, Carvalho R, et al. E-cadherin gene (CDH1) promoter methylation as the second hit in sporadic diffuse gastric carcinoma. Oncogene 2001;20:1525-8
   PubMed Web of Science ®Google Scholar
• Liu YC, Shen CY, Wu HS, et al. Mechanisms inactivating the gene for E-cadherin in sporadic gastric carcinomas. World J Gastroenterol 2006;12:2168-73
   PubMed Web of Science ®Google Scholar
• Ascano JJ, Frierson H Jr, Moskaluk CA, et al. Inactivation of the E-cadherin gene in sporadic diffuse-type gastric cancer. Mod Pathol 2001;14:942-9
   PubMed Web of Science ®Google Scholar
• Graziano F, Arduini F, Ruzzo A, et al. Combined analysis of E-cadherin gene (CDH1) promoter hypermethylation and E-cadherin protein expression in patients with gastric cancer: implications for treatment with demethylating drugs. Ann Oncol 2004;15:489-92
   PubMed Web of Science ®Google Scholar
• Corso G, Roviello F, Paredes J, et al. Characterization of the P373L E-cadherin germline missense mutation and implication for clinical management. Eur J Surg Oncol 2007;33:1061-7
   PubMed Web of Science ®Google Scholar
• Tamura G, Yin J, Wang S, et al. E-Cadherin gene promoter hypermethylation in primary human gastric carcinomas. J Natl Cancer Inst 2000;92:569-73
   PubMed Web of Science ®Google Scholar
• Ambros V. The functions of animal microRNAs. Nature 2004;431:350-5
   PubMed Web of Science ®Google Scholar
• He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 2004;5:522-31
   PubMed Web of Science ®Google Scholar
• Hurteau GJ, Carlson JA, Spivack SD, Brock GJ. Overexpression of the microRNA hsa-miR-200c leads to reduced expression of transcription factor 8 and increased expression of E-cadherin. Cancer Res 2007;67:7972-6
   PubMed Web of Science ®Google Scholar
• Korpal M, Lee ES, Hu G, Kang Y. The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem 2008;283:14910-14
   PubMed Web of Science ®Google Scholar
• Gregory PA, Bert AG, Paterson EL, et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008;10:593-601
   PubMed Web of Science ®Google Scholar
• Park SM, Gaur AB, Lengyel E, Peter ME. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev 2008;22:894-907
   PubMed Web of Science ®Google Scholar
• Tan HX, Wang Q, Chen LZ, et al. MicroRNA-9 reduces cell invasion and E-cadherin secretion in SK-Hep-1 cell. Med Oncol 2010;27:654-60
   PubMed Web of Science ®Google Scholar
• Li X, Zhang Y, Ding J, et al. Survival prediction of gastric cancer by a seven-microRNA signature. Gut 2010;59:579-85
   PubMed Web of Science ®Google Scholar
• Ueda T, Volinia S, Okumura H, et al. Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. Lancet Oncol 2010;11:136-46
   PubMed Web of Science ®Google Scholar
• Rotkrua P, Shimada S, Mogushi K, et al. Circulating microRNAs as biomarkers for early detection of diffuse-type gastric cancer using a mouse model. Br J Cancer 2013;108:932-40
   PubMed Web of Science ®Google Scholar
• Garofalo M, Croce CM. MicroRNAs as therapeutic targets in chemoresistance. Drug Resist Updat 2013; [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Hua H, Li M, Luo T, et al. Matrix metalloproteinases in tumorigenesis: an evolving paradigm. Cell Mol Life Sci 2011;68:3853-68
   PubMed Web of Science ®Google Scholar
• Radisky DC, Levy DD, Littlepage LE, et al. Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature 2005;436:123-7
   PubMed Web of Science ®Google Scholar
• Lee KH, Choi EY, Hyun MS, et al. Association of extracellular cleavage of E-cadherin mediated by MMP-7 with HGF-induced in vitro invasion in human stomach cancer cells. Eur Surg Res 2007;39:208-15
   PubMed Web of Science ®Google Scholar
• Noe V, Fingleton B, Jacobs K, et al. Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1. J Cell Sci 2001;114:111-18
   PubMed Web of Science ®Google Scholar
• Maretzky T, Reiss K, Ludwig A, et al. ADAM10 mediates E-cadherin shedding and regulates epithelial cell-cell adhesion, migration, and beta-catenin translocation. Proc Natl Acad Sci USA 2005;102:9182-7
   PubMed Web of Science ®Google Scholar
• Cowden Dahl KD, Symowicz J, Ning Y, et al. Matrix metalloproteinase 9 is a mediator of epidermal growth factor-dependent e-cadherin loss in ovarian carcinoma cells. Cancer Res 2008;68:4606-13
   PubMed Web of Science ®Google Scholar
• Najy AJ, Day KC, Day ML. The ectodomain shedding of E-cadherin by ADAM15 supports ErbB receptor activation. J Biol Chem 2008;283:18393-401
   PubMed Web of Science ®Google Scholar
• Symowicz J, Adley BP, Gleason KJ, et al. Engagement of collagen-binding integrins promotes matrix metalloproteinase-9-dependent E-cadherin ectodomain shedding in ovarian carcinoma cells. Cancer Res 2007;67:2030-9
   PubMed Web of Science ®Google Scholar
• Johnson SK, Ramani VC, Hennings L, Haun RS. Kallikrein 7 enhances pancreatic cancer cell invasion by shedding E-cadherin. Cancer 2007;109:1811-20
   PubMed Web of Science ®Google Scholar
• Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. Carcinogenesis 2010;31:27-36
   PubMed Web of Science ®Google Scholar
• Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004;429:457-63
   PubMed Web of Science ®Google Scholar
• Kristensen LS, Nielsen HM, Hansen LL. Epigenetics and cancer treatment. Eur J Pharmacol 2009;625:131-42
   PubMed Web of Science ®Google Scholar
• Cortez CC, Jones PA. Chromatin, cancer and drug therapies. Mutat Res 2008;647:44-51
   PubMed Web of Science ®Google Scholar
• Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009;10:223-32
   PubMed Web of Science ®Google Scholar
• Gottlicher M, Minucci S, Zhu P, et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 2001;20:6969-78
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006;106:1794-803
   PubMed Web of Science ®Google Scholar
• Steele NL, Plumb JA, Vidal L, et al. A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin Cancer Res 2008;14:804-10
   PubMed Web of Science ®Google Scholar
• Chiba T, Yokosuka O, Arai M, et al. Identification of genes up-regulated by histone deacetylase inhibition with cDNA microarray and exploration of epigenetic alterations on hepatoma cells. J Hepatol 2004;41:436-45
   PubMed Web of Science ®Google Scholar
• Dannenberg LO, Edenberg HJ. Epigenetics of gene expression in human hepatoma cells: expression profiling the response to inhibition of DNA methylation and histone deacetylation. BMC Genomics 2006;7:181
   PubMed Web of Science ®Google Scholar
• Gregory DJ, Mikhaylova L, Fedulov AV. Selective DNA demethylation by fusion of TDG with a sequence-specific DNA-binding domain. Epigenetics 2012;7:344-9
   PubMed Web of Science ®Google Scholar
• Bordeira-Carrico R, Pego AP, Santos M, Oliveira C. Cancer syndromes and therapy by stop-codon readthrough. Trends Mol Med 2012;18:667-78
   PubMed Web of Science ®Google Scholar
• Capone JP, Sharp PA, RajBhandary UL. Amber, ochre and opal suppressor tRNA genes derived from a human serine tRNA gene. EMBO J 1985;4:213-21
   PubMed Web of Science ®Google Scholar
• Kellermayer R. Translational readthrough induction of pathogenic nonsense mutations. Eur J Med Genet 2006;49:445-50
   PubMed Web of Science ®Google Scholar
• Lee HL, Dougherty JP. Pharmaceutical therapies to recode nonsense mutations in inherited diseases. Pharmacol Ther 2012;136:227-66
   PubMed Web of Science ®Google Scholar
• Welch EM, Barton ER, Zhuo J, et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature 2007;447:87-91
   PubMed Web of Science ®Google Scholar
• Floquet C, Deforges J, Rousset JP, Bidou L. Rescue of non-sense mutated p53 tumor suppressor gene by aminoglycosides. Nucleic Acids Res 2011;39:3350-62
   PubMed Web of Science ®Google Scholar
• Keeling KM, Bedwell DM. Clinically relevant aminoglycosides can suppress disease-associated premature stop mutations in the IDUA and P53 cDNAs in a mammalian translation system. J Mol Med 2002;80:367-76
   PubMed Web of Science ®Google Scholar
• Zilberberg A, Lahav L, Rosin-Arbesfeld R. Restoration of APC gene function in colorectal cancer cells by aminoglycoside- and macrolide-induced read-through of premature termination codons. Gut 2010;59:496-507
   PubMed Web of Science ®Google Scholar
• Kerem E, Hirawat S, Armoni S, et al. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Lancet 2008;372:719-27
   PubMed Web of Science ®Google Scholar
• Sermet-Gaudelus I, Boeck KD, Casimir GJ, et al. Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis. Am J Respir Crit Care Med 2010;182:1262-72
   PubMed Web of Science ®Google Scholar
• Wilschanski M, Miller LL, Shoseyov D, et al. Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis. Eur Respir J 2011;38:59-69
   PubMed Web of Science ®Google Scholar
• Minde DP, Anvarian Z, Rudiger SG, Maurice MM. Messing up disorder: how do missense mutations in the tumor suppressor protein APC lead to cancer? Mol Cancer 2011;10:101
   PubMed Web of Science ®Google Scholar
• Suriano G, Oliveira C, Ferreira P, et al. Identification of CDH1 germline missense mutations associated with functional inactivation of the E-cadherin protein in young gastric cancer probands. Hum Mol Genet 2003;12:575-82
   PubMed Web of Science ®Google Scholar
• Suriano G, Seixas S, Rocha J, Seruca R. A model to infer the pathogenic significance of CDH1 germline missense variants. J Mol Med 2006;84:1023-31
   PubMed Web of Science ®Google Scholar
• Figueiredo J, Simoes-Correia J, Soderberg O, et al. ADP-ribosylation factor 6 mediates E-cadherin recovery by chemical chaperones. PLoS One 2011;6:e23188
   PubMed Web of Science ®Google Scholar
• Mateus AR, Simoes-Correia J, Figueiredo J, et al. E-cadherin mutations and cell motility: a genotype-phenotype correlation. Exp Cell Res 2009;315:1393-402
   PubMed Web of Science ®Google Scholar
• Simoes-Correia J, Figueiredo J, Oliveira C, et al. Endoplasmic reticulum quality control: a new mechanism of E-cadherin regulation and its implication in cancer. Hum Mol Genet 2008;17:3566-76
   PubMed Web of Science ®Google Scholar
• Nudelman I, Glikin D, Smolkin B, et al. Repairing faulty genes by aminoglycosides: development of new derivatives of geneticin (G418) with enhanced suppression of diseases-causing nonsense mutations. Bioorg Med Chem 2010;18:3735-46
   PubMed Web of Science ®Google Scholar
• Nudelman I, Rebibo-Sabbah A, Cherniavsky M, et al. Development of novel aminoglycoside (NB54) with reduced toxicity and enhanced suppression of disease-causing premature stop mutations. J Med Chem 2009;52:2836-45
   PubMed Web of Science ®Google Scholar
• Thiery JP. Cell adhesion in development: a complex signaling network. Curr Opin Genet Dev 2003;13:365-71
   PubMed Web of Science ®Google Scholar
• Cavallaro U, Dejana E. Adhesion molecule signalling: not always a sticky business. Nat Rev Mol Cell Biol 2011;12:189-97
   PubMed Web of Science ®Google Scholar
• Yap AS, Kovacs EM. Direct cadherin-activated cell signaling: a view from the plasma membrane. J Cell Biol 2003;160:11-16
   PubMed Web of Science ®Google Scholar
• Christofori G. New signals from the invasive front. Nature 2006;441:444-50
   PubMed Web of Science ®Google Scholar
• Nelson WJ, Nusse R. Convergence of Wnt, beta-catenin, and cadherin pathways. Science 2004;303:1483-7
   PubMed Web of Science ®Google Scholar
• Polakis P. Wnt signaling in cancer. Cold Spring Harb Perspect Biol 2012;4(5): pii: a008052
   PubMed Web of Science ®Google Scholar
• Jeanes A, Gottardi CJ, Yap AS. Cadherins and cancer: how does cadherin dysfunction promote tumor progression? Oncogene 2008;27:6920-9
   PubMed Web of Science ®Google Scholar
• Jordaan G, Liao W, Sharma S. E-cadherin gene re-expression in chronic lymphocytic leukemia cells by HDAC inhibitors. BMC Cancer 2013;13:88
   PubMed Web of Science ®Google Scholar
• Miyazawa K, Iwaya K, Kuroda M, et al. Nuclear accumulation of beta-catenin in intestinal-type gastric carcinoma: correlation with early tumor invasion. Virchows Arch 2000;437:508-13
   PubMed Web of Science ®Google Scholar
• Utsunomiya T, Doki Y, Takemoto H, et al. Clinical significance of disordered beta-catenin expression pattern in human gastric cancers. Gastric Cancer 2000;3:193-201
   PubMedGoogle Scholar
• Ohene-Abuakwa Y, Noda M, Perenyi M, et al. Expression of the E-cadherin/catenin (alpha-, beta-, and gamma-) complex correlates with the macroscopic appearance of early gastric cancer. J Pathol 2000;192:433-9
   PubMed Web of Science ®Google Scholar
• Bauer L, Langer R, Becker K, et al. Expression profiling of stem cell-related genes in neoadjuvant-treated gastric cancer: a NOTCH2, GSK3B and beta-catenin gene signature predicts survival. PLoS One 2012;7:e44566
   PubMed Web of Science ®Google Scholar
• Radulescu S, Ridgway RA, Cordero J, et al. Acute WNT signalling activation perturbs differentiation within the adult stomach and rapidly leads to tumour formation. Oncogene 2013;32:2048-57
   PubMed Web of Science ®Google Scholar
• Shi Y, Paluch BE, Wang X, Jiang X. PTEN at a glance. J Cell Sci 2012;125:4687-92
   PubMed Web of Science ®Google Scholar
• Trotman LC, Niki M, Dotan ZA, et al. Pten dose dictates cancer progression in the prostate. PLoS Biol 2003;1:E59
   PubMed Web of Science ®Google Scholar
• Wu X, Hepner K, Castelino-Prabhu S, et al. Evidence for regulation of the PTEN tumor suppressor by a membrane-localized multi-PDZ domain containing scaffold protein MAGI-2. Proc Natl Acad Sci USA 2000;97:4233-8
   PubMed Web of Science ®Google Scholar
• Subauste MC, Nalbant P, Adamson ED, Hahn KM. Vinculin controls PTEN protein level by maintaining the interaction of the adherens junction protein beta-catenin with the scaffolding protein MAGI-2. J Biol Chem 2005;280:5676-81
   PubMed Web of Science ®Google Scholar
• Fournier MV, Fata JE, Martin KJ, et al. Interaction of E-cadherin and PTEN regulates morphogenesis and growth arrest in human mammary epithelial cells. Cancer Res 2009;69:4545-52
   PubMed Web of Science ®Google Scholar
• Lau MT, Klausen C, Leung PC. E-cadherin inhibits tumor cell growth by suppressing PI3K/Akt signaling via beta-catenin-Egr1-mediated PTEN expression. Oncogene 2011;30:2753-66
   PubMed Web of Science ®Google Scholar
• Yang TS, Yang XH, Wang XD, et al. MiR-214 regulate gastric cancer cell proliferation, migration and invasion by targeting PTEN. Cancer Cell Int 2013;13:68
   PubMed Web of Science ®Google Scholar
• Zhu X, Qin X, Fei M, et al. Loss and reduced expression of PTEN correlate with advanced-stage gastric carcinoma. Exp Ther Med 2013;5:57-64
   PubMed Web of Science ®Google Scholar
• Fei G, Ebert MP, Mawrin C, et al. Reduced PTEN expression in gastric cancer and in the gastric mucosa of gastric cancer relatives. Eur J Gastroenterol Hepatol 2002;14:297-303
   PubMed Web of Science ®Google Scholar
• Yang L, Kuang LG, Zheng HC, et al. PTEN encoding product: a marker for tumorigenesis and progression of gastric carcinoma. World J Gastroenterol 2003;9:35-9
   PubMed Web of Science ®Google Scholar
• Watabe M, Nagafuchi A, Tsukita S, Takeichi M. Induction of polarized cell-cell association and retardation of growth by activation of the E-cadherin-catenin adhesion system in a dispersed carcinoma line. J Cell Biol 1994;127:247-56
   PubMed Web of Science ®Google Scholar
• Qian X, Karpova T, Sheppard AM, et al. E-cadherin-mediated adhesion inhibits ligand-dependent activation of diverse receptor tyrosine kinases. Embo J 2004;23:1739-48
   PubMed Web of Science ®Google Scholar
• Perrais M, Chen X, Perez-Moreno M, Gumbiner BM. E-cadherin homophilic ligation inhibits cell growth and epidermal growth factor receptor signaling independently of other cell interactions. Mol Biol Cell 2007;18:2013-25
   PubMed Web of Science ®Google Scholar
• Andl CD, Rustgi AK. No one-way street: cross-talk between e-cadherin and receptor tyrosine kinase (RTK) signaling: a mechanism to regulate RTK activity. Cancer Biol Ther 2005;4:28-31
   PubMed Web of Science ®Google Scholar
• Bremm A, Walch A, Fuchs M, et al. Enhanced activation of epidermal growth factor receptor caused by tumor-derived E-cadherin mutations. Cancer Res 2008;68:707-14
   PubMed Web of Science ®Google Scholar
• Mateus AR, Seruca R, Machado JC, et al. EGFR regulates RhoA-GTP dependent cell motility in E-cadherin mutant cells. Hum Mol Genet 2007;16:1639-47
   PubMed Web of Science ®Google Scholar
• Moon WS, Tarnawski AS, Chai J, et al. Reduced expression of epidermal growth factor receptor related protein in gastric cancer. Gut 2005;54:201-6
   PubMed Web of Science ®Google Scholar
• Zhang S, Yu D. Targeting Src family kinases in anti-cancer therapies: turning promise into triumph. Trends Pharmacol Sci 2012;33:122-8
   PubMed Web of Science ®Google Scholar
• Alt-Holland A, Sowalsky AG, Szwec-Levin Y, et al. Suppression of E-cadherin function drives the early stages of Ras-induced squamous cell carcinoma through upregulation of FAK and Src. J Invest Dermatol 2011;131:2306-15
   PubMed Web of Science ®Google Scholar
• Serrels A, Canel M, Brunton VG, Frame MC. Src/FAK-mediated regulation of E-cadherin as a mechanism for controlling collective cell movement: insights from in vivo imaging. Cell Adh Migr 2011;5:360-5
   PubMed Web of Science ®Google Scholar
• Giaginis CT, Vgenopoulou S, Tsourouflis GS, et al. Expression and clinical significance of focal adhesion kinase in the two distinct histological types, intestinal and diffuse, of human gastric adenocarcinoma. Pathol Oncol Res 2009;15:173-81
   PubMed Web of Science ®Google Scholar
• Park JH, Lee BL, Yoon J, et al. Focal adhesion kinase (FAK) gene amplification and its clinical implications in gastric cancer. Hum Pathol 2010;41:1664-73
   PubMed Web of Science ®Google Scholar
• Chen Y, Xia X, Wang S, et al. High FAK combined with low JWA expression: clinical prognostic and predictive role for adjuvant fluorouracil-leucovorin-oxaliplatin treatment in resectable gastric cancer patients. J Gastroenterol 2013; [Epub ahead of print]
   Web of Science ®Google Scholar
• Lai IR, Chu PY, Lin HS, et al. Phosphorylation of focal adhesion kinase at Tyr397 in gastric carcinomas and its clinical significance. Am J Pathol 2010;177:1629-37
   PubMed Web of Science ®Google Scholar
• Schlaepfer DD, Hauck CR, Sieg DJ. Signaling through focal adhesion kinase. Prog Biophys Mol Biol 1999;71:435-78
   PubMed Web of Science ®Google Scholar
• Humar B, Fukuzawa R, Blair V, et al. Destabilized adhesion in the gastric proliferative zone and c-Src kinase activation mark the development of early diffuse gastric cancer. Cancer Res 2007;67:2480-9
   PubMed Web of Science ®Google Scholar
• Ingham PW, McMahon AP. Hedgehog signaling in animal development: paradigms and principles. Genes Dev 2001;15:3059-87
   PubMed Web of Science ®Google Scholar
• Fukaya M, Isohata N, Ohta H, et al. Hedgehog signal activation in gastric pit cell and in diffuse-type gastric cancer. Gastroenterology 2006;131:14-29
   PubMed Web of Science ®Google Scholar
• Ohta H, Aoyagi K, Fukaya M, et al. Cross talk between hedgehog and epithelial-mesenchymal transition pathways in gastric pit cells and in diffuse-type gastric cancers. Br J Cancer 2009;100:389-98
   PubMed Web of Science ®Google Scholar
• Ma X, Chen K, Huang S, et al. Frequent activation of the hedgehog pathway in advanced gastric adenocarcinomas. Carcinogenesis 2005;26:1698-705
   PubMed Web of Science ®Google Scholar
• Xiao C, Ogle SA, Schumacher MA, et al. Hedgehog signaling regulates E-cadherin expression for the maintenance of the actin cytoskeleton and tight junctions. Am J Physiol Gastrointest Liver Physiol 2010;299:G1252-65
   PubMed Web of Science ®Google Scholar
• Geisbrecht ER, Sawant K, Su Y, et al. Genetic interaction screens identify a role for hedgehog signaling in Drosophila border cell migration. Dev Dyn 2013;242:414-31
   PubMed Web of Science ®Google Scholar
• Watanabe T, Sato K, Kaibuchi K. Cadherin-mediated intercellular adhesion and signaling cascades involving small GTPases. Cold Spring Harb Perspect Biol 2009;1:a003020
   PubMed Web of Science ®Google Scholar
• Menke A, Giehl K. Regulation of adherens junctions by Rho GTPases and p120-catenin. Arch Biochem Biophys 2012;524:48-55
   PubMed Web of Science ®Google Scholar
• Pan Y, Bi F, Liu N, et al. Expression of seven main Rho family members in gastric carcinoma. Biochem Biophys Res Commun 2004;315:686-91
   PubMed Web of Science ®Google Scholar
• Guarino M, Rubino B, Ballabio G. The role of epithelial-mesenchymal transition in cancer pathology. Pathology 2007;39:305-18
   PubMed Web of Science ®Google Scholar
• Gialeli C, Theocharis AD, Karamanos NK. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. Febs J 2011;278:16-27
   PubMed Web of Science ®Google Scholar
• Ferreira P, Oliveira MJ, Beraldi E, et al. Loss of functional E-cadherin renders cells more resistant to the apoptotic agent taxol in vitro. Exp Cell Res 2005;310:99-104
   PubMed Web of Science ®Google Scholar
• Ferreira AC, Suriano G, Mendes N, et al. E-cadherin impairment increases cell survival through Notch-dependent upregulation of Bcl-2. Hum Mol Genet 2012;21:334-43
   PubMed Web of Science ®Google Scholar
• Tiwari N, Gheldof A, Tatari M, Christofori G. EMT as the ultimate survival mechanism of cancer cells. Semin Cancer Biol 2012;22:194-207
   PubMed Web of Science ®Google Scholar
• Kleizen B, Braakman I. Protein folding and quality control in the endoplasmic reticulum. Curr Opin Cell Biol 2004;16:343-9
   PubMed Web of Science ®Google Scholar
• Meusser B, Hirsch C, Jarosch E, Sommer T. ERAD: the long road to destruction. Nat Cell Biol 2005;7:766-72
   PubMed Web of Science ®Google Scholar
• Vembar SS, Brodsky JL. One step at a time: endoplasmic reticulum-associated degradation. Nat Rev Mol Cell Biol 2008;9:944-57
   PubMed Web of Science ®Google Scholar
• Bernasconi R, Molinari M. ERAD and ERAD tuning: disposal of cargo and of ERAD regulators from the mammalian ER. Curr Opin Cell Biol 2011;23:176-83
   PubMed Web of Science ®Google Scholar
• Aebi M, Bernasconi R, Clerc S, Molinari M. N-glycan structures: recognition and processing in the ER. Trends Biochem Sci 2010;35:74-82
   PubMed Web of Science ®Google Scholar
• Zhou F, Su J, Fu L, et al. Unglycosylation at Asn-633 made extracellular domain of E-cadherin folded incorrectly and arrested in endoplasmic reticulum, then sequentially degraded by ERAD. Glycoconj J 2008;25:727-40
   PubMed Web of Science ®Google Scholar
• Chaudhuri TK, Paul S. Protein-misfolding diseases and chaperone-based therapeutic approaches. FEBS J 2006;273:1331-49
   PubMed Web of Science ®Google Scholar
• Bartolini M, Andrisano V. Strategies for the inhibition of protein aggregation in human diseases. Chembiochem 2010;11:1018-35
   PubMed Web of Science ®Google Scholar
• Boelens J, Lust S, Offner F, et al. Review. The endoplasmic reticulum: a target for new anticancer drugs. In vivo 2007;21:215-26
   PubMed Web of Science ®Google Scholar
• Engin F, Hotamisligil GS. Restoring endoplasmic reticulum function by chemical chaperones: an emerging therapeutic approach for metabolic diseases. Diabetes Obes Metab 2010;12(Suppl 2):108-15
   PubMed Web of Science ®Google Scholar
• Simoes-Correia J, Figueiredo J, Lopes R, et al. E-cadherin destabilization accounts for the pathogenicity of missense mutations in hereditary diffuse gastric cancer. PLoS One 2012;7:e33783
   PubMed Web of Science ®Google Scholar
• Figueiredo J, Soderberg O, Simoes-Correia J, et al. The importance of E-cadherin binding partners to evaluate the pathogenicity of E-cadherin missense mutations associated to HDGC. Eur J Hum Genet 2013;21:301-9
   PubMed Web of Science ®Google Scholar
• Ling K, Bairstow SF, Carbonara C, et al. Type Igamma phosphatidylinositol phosphate kinase modulates adherens junction and E-cadherin trafficking via a direct interaction with mu 1B adaptin. J Cell Biol 2007;176:343-53
   PubMed Web of Science ®Google Scholar
• Stemmler MP. Cadherins in development and cancer. Mol Biosyst 2008;4:835-50
   PubMedGoogle Scholar
• Mimeault M, Batra SK. Frequent deregulations in the hedgehog signaling network and cross-talks with the epidermal growth factor receptor pathway involved in cancer progression and targeted therapies. Pharmacol Rev 2010;62:497-524
   PubMed Web of Science ®Google Scholar
• Atmaca A, Werner D, Pauligk C, et al. The prognostic impact of epidermal growth factor receptor in patients with metastatic gastric cancer. BMC Cancer 2012;12:524
   PubMed Web of Science ®Google Scholar
• Terashima M, Kitada K, Ochiai A, et al. Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer. Clin Cancer Res 2012;18:5992-6000
   PubMed Web of Science ®Google Scholar
• Yoong J, Michael M, Leong T. Targeted therapies for gastric cancer: current status. Drugs 2011;71:1367-84
   PubMed Web of Science ®Google Scholar
• Purow B. Notch inhibition as a promising new approach to cancer therapy. Adv Exp Med Biol 2012;727:305-19
   PubMed Web of Science ®Google Scholar
• Piazzi G, Fini L, Selgrad M, et al. Epigenetic regulation of Delta-Like1 controls Notch1 activation in gastric cancer. Oncotarget 2011;2:1291-301
   PubMedGoogle Scholar
• Liu Z, Turkoz A, Jackson EN, et al. Notch1 loss of heterozygosity causes vascular tumors and lethal hemorrhage in mice. J Clin Invest 2011;121:800-8
   PubMed Web of Science ®Google Scholar
• Brouxhon SM, Kyrkanides S, Teng X, et al. Monoclonal Antibody against the Ectodomain of E-Cadherin (DECMA-1) Suppresses Breast Carcinogenesis: involvement of the HER/PI3K/Akt/mTOR and IAP Pathways. Clin Cancer Res 2013;19:3234-46
   PubMed Web of Science ®Google Scholar